Varenicline Tartrate Patent Expiration
Varenicline Tartrate is Used for treating dry eye disease symptoms. It was first introduced by Pf Prism Cv
Varenicline Tartrate Patents
Given below is the list of patents protecting Varenicline Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tyrvaya | US10456396 | Dry eye treatments | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US11224598 | Methods of increasing lacrimal proteins | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US11903941 | Compositions and use of varenicline for treating dry eye | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US11903942 | Compositions and use of varenicline for treating dry eye | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US11903943 | Compositions and use of varenicline for treating dry eye | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US11911380 | Compositions and use of varenicline for treating dry eye | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US9504644 | Methods of increasing tear production | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US9504645 | Pharmaceutical formulations for treating ocular conditions | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US9532944 | Methods of improving ocular discomfort | Oct 19, 2035 | Oyster Point Pharma |
| Tyrvaya | US9597284 | Dry eye treatments | Oct 19, 2035 | Oyster Point Pharma |
| Chantix |
US7265119 (Pediatric) | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb 03, 2023
(Expired) | Pf Prism Cv |
| Chantix |
US6890927 (Pediatric) | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov 06, 2022
(Expired) | Pf Prism Cv |
| Chantix | US7265119 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug 03, 2022
(Expired) | Pf Prism Cv |
| Chantix | US6890927 | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May 06, 2022
(Expired) | Pf Prism Cv |
| Chantix |
US6410550 (Pediatric) | Aryl fused azapolycyclic compounds |
Nov 10, 2020
(Expired) | Pf Prism Cv |
| Chantix | US6410550 | Aryl fused azapolycyclic compounds |
May 10, 2020
(Expired) | Pf Prism Cv |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Varenicline Tartrate's patents.
Latest Legal Activities on Varenicline Tartrate's Patents
Given below is the list recent legal activities going on the following patents of Varenicline Tartrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2024 | US9532944 |
| Patent eCofC Notification | 04 Jun, 2024 | US11903942 |
| Email Notification Critical
| 04 Jun, 2024 | US11903942 |
| Recordation of Patent eCertificate of Correction | 04 Jun, 2024 | US11903942 |
| Mail Patent eCofC Notification | 04 Jun, 2024 | US11903942 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2024 | US9504645 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2024 | US9504644 |
| Post Issue Communication - Certificate of Correction | 15 May, 2024 | US11903942 |
| Patent eGrant Notification | 27 Feb, 2024 | US11911380 |
| Mail Patent eGrant Notification | 27 Feb, 2024 | US11911380 |
Varenicline Tartrate's Family Patents
